Detalhe da pesquisa
1.
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Acta Neuropathol
; 147(1): 2, 2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066305
2.
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
Curr Opin Oncol
; 34(6): 653-660, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000367
3.
Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study.
Br J Clin Pharmacol
; 88(11): 4941-4949, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36028463
4.
Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Neurol Sci
; 43(3): 2031-2041, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424427
5.
Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients.
Neurol Sci
; 42(5): 1879-1886, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954462
6.
Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Curr Opin Oncol
; 32(6): 603-612, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852312
7.
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.
Curr Opin Neurol
; 31(6): 727-732, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30239358
8.
Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.
Acta Neuropathol
; 146(6): 849-852, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851269
9.
Late-onset vascular complications of radiotherapy for primary brain tumors: a case-control and cross-sectional analysis.
J Cancer Surviv
; 18(1): 59-67, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142871
10.
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Eur J Cancer
; 202: 114034, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38537315
11.
Advances in molecular and imaging biomarkers in lower-grade gliomas.
Expert Rev Neurother
; 23(12): 1217-1231, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37982735
12.
Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
Cancers (Basel)
; 15(23)2023 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38067258
13.
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy.
Nat Cancer
; 4(2): 181-202, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732634
14.
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
Brain Commun
; 5(3): fcad169, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37389303
15.
Innovating Strategies and Tailored Approaches in Neuro-Oncology.
Cancers (Basel)
; 14(5)2022 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267432
16.
Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors.
Neurol Neuroimmunol Neuroinflamm
; 8(6)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34497101
17.
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors.
Neurol Neuroimmunol Neuroinflamm
; 8(3)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637598
18.
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
Neuro Oncol
; 22(11): 1614-1624, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32413119
19.
Current therapeutic approaches to diffuse grade II and III gliomas.
Ther Adv Neurol Disord
; 11: 1756285617752039, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29403544
20.
The clinical use of IDH1 and IDH2 mutations in gliomas.
Expert Rev Mol Diagn
; 18(12): 1041-1051, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30427756